No Data
Sector Update: Health Care Stocks Fall Pre-Bell Monday
BeiGene Secures Positive CHMP Opinion For TEVIMBRA As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer
Express News | Beigene Receives Positive Chmp Opinion for Tevimbra® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
BEIGENE (06160.HK) issued 0.1687 million shares due to the restricted share units vesting.
On March 31, Glorious Exchange reported that BEIGENE (06160.HK) announced the issuance of 0.1687 million ordinary shares on March 28, 2025, due to the vesting of restricted share units granted under the equity plan (excluding the company's directors).
Tianfeng recommends continuing to focus on Innovative Drugs and suggests paying attention to companies with BIC potential on a Global scale.
Why Innovative Drugs? Tianfeng provided three reasons.
BeiGene Net Loss Narrows 27% in 2024
